Holen Sie sich die Stockscreener-App
3.21
3.55%
0.11
Handel nachbörslich:
3.37
0.16
+4.98%
Schlusskurs vom Vortag:
$3.10
Offen:
$3.1
24-Stunden-Volumen:
201.89K
Relative Volume:
2.90
Marktkapitalisierung:
$31.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-42.19M
KGV:
-5.0952
EPS:
-0.63
Netto-Cashflow:
$-25.32M
1W Leistung:
+0.63%
1M Leistung:
+6.64%
6M Leistung:
-11.57%
1J Leistung:
-62.19%
1-Tages-Spanne:
$3.10
$3.56
1-Wochen-Bereich:
$3.10
$3.74
52-Wochen-Spanne:
$2.16
$69.99
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Firmenname
Sab Biotherapeutics Inc
Sektor
Branche
Telefon
305-845-2813
Adresse
777 W 41ST ST, MIAMI BEACH
Vergleichen Sie SABS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| SABS | 3.21 | 31.10M | 0 | -42.19M | -25.32M | -0.63 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-11-05 | Eingeleitet | Chardan Capital Markets | Buy |
Sab Biotherapeutics Inc Aktie (SABS) Neueste Nachrichten
SABS FY2024 EPS Reduced by Brookline Capital Management - Defense World
SAB Biotherapeutics Third Quarter 2024 Earnings: US$1.12 loss per share (vs US$0.97 loss in 3Q 2023) - Yahoo Finance
SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update - GlobeNewswire
SAB Bio's Q3 Loss Widens to $10.3M Despite Progress in Diabetes Drug Trial | SABS Stock News - StockTitan
SAB BIO CEO to Participate in Fireside Chat at Guggenheim Securities Healthcare Innovation Conference - GlobeNewswire
Critical Comparison: Sana Biotechnology (NASDAQ:SANA) & SAB Biotherapeutics (NASDAQ:SABS) - Defense World
SAB Biotherapeutics Inc (SABS) Getting Ready To Launch, Waiting For The Long Term Buyers - Stocks Register
Influenza Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABS) Declines By 12.7% - Defense World
Saba Capital Income & Opportunities Fund II (NYSE:SABA) Major Shareholder Sells $37,672.38 in Stock - Defense World
Metric Analysis: Cassava Sciences Inc (SAVA)’s Key Ratios in the Limelight - The Dwinnex
Healthy Upside Potential: Sabre Corp (SABR) - SETE News
Assembly Biosciences keeps Neutral rating after Phase 1a study results - Investing.com
DSMB endorses continuation of Alzheimer's drug trials - Investing.com India
Cassava Sciences Unusual Options Activity For September 23 - Benzinga
SAB Biotherapeutics (NASDAQ:SABS) Will Have To Spend Its Cash Wisely - Yahoo Finance
Renaissance Technologies LLC Lowers Stock Position in SBA Communications Co. (NASDAQ:SBAC) - Defense World
Sabre Corporation (SABR): Among the Worst AI Stocks To Buy Under $10 - Yahoo Finance
Acumen Health Holdings ("Acumen") to Acquire the Avenova brand from NovaBay Pharmaceuticals - Morningstar
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Oppenheimer - Defense World
SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Short Interest Update - Defense World
SAB BIO CEO to Participate in Fireside Chat at 2024 Cantor Global Healthcare Conference - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Given “Buy” Rating at Chardan Capital - Defense World
SAB BIO Provides SAB-142 Clinical Trial Progress Update at - GlobeNewswire
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the - The Bakersfield Californian
SAB BIO Provides SAB-142 Clinical Trial Progress Update at the European Association for the Study of Diabetes Annual Meeting - StockTitan
SAB BIO to Present at the European Association for the Study of Diabetes 60th Annual Meeting - GlobeNewswire
SAB Biotherapeutics (NASDAQ:SABS) Coverage Initiated by Analysts at Oppenheimer - Defense World
How To Buy SAB Biotherapeutics, Inc. Stock Online in August 2024 - Traders Union
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG - Barchart
Influenza Pipeline Drugs 2024 | Moderna, SAB Biotherapeutics, - openPR
Chardan Capital Analysts Boost Earnings Estimates for SAB Biotherapeutics, Inc. (NASDAQ:SABS) - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Receives Buy Rating from HC Wainwright - Defense World
SAB Biotherapeutics (NASDAQ:SABS) Stock Rating Reaffirmed by Chardan Capital - Defense World
SABS stock touches 52-week low at $2.3 amid market challenges - Investing.com
SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates - GlobeNewswire
Seasonal Influenza Treatment Market Size 2032 | SAb - openPR
SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes - GlobeNewswire
SAB BIO Appoints Lucy To as Chief Financial Officer - citybiz
SAB Biotherapeutics (NASDAQ:SABS) Trading Down 0.4% - American Banking and Market News
MarketBeat June market recap - SiouxFalls.Business
SAB Biotherapeutics to Present at the Ladenburg Thalmann Annual Healthcare Conference 2021 - Quantisnow
Big Cypress Acquisition Corp. Reports Ladenburg Conference Presentation by Planned Merger Partner SAB Biotherapeutics - Quantisnow
SAB Biotherapeutics Announces Publication of Preclinical Data Demonstrating SAB-185 Effectively Neutralizes SARS ... - Quantisnow
SAB Biotherapeutics Announces Nonclinical Data Demonstrating SAB-185 Potently Neutralizes Delta and Lambda ... - Quantisnow
SAB Biotherapeutics to List on Nasdaq through Merger with Big Cypress Acquisition Corp., Advancing Unique Human ... - Quantisnow
Reviewing SAB Biotherapeutics (NASDAQ:SABS) & Quantum Genomics Société Anonyme (OTCMKTS:QNNTF) - Defense World
Cathie Wood's ARK ETF focuses on PagerDuty, 10X Genomics stock By Investing.com - Investing.com
Tenaya Therapeutics Announces Director Resignation By Investing.com - Investing.com
CSP Inc insider buys shares worth over $23,000 - Investing.com
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Finanzdaten der Sab Biotherapeutics Inc-Aktie (SABS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):